1. Home
  2. QLEP vs TTRX Comparison

QLEP vs TTRX Comparison

Compare QLEP & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QLEP

Quantum Leap Acquisition Corp Class A Ordinary Shares

N/A

Current Price

$10.08

Market Cap

301.6M

Sector

N/A

ML Signal

N/A

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$9.30

Market Cap

298.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QLEP
TTRX
Founded
2025
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
301.6M
298.8M
IPO Year
2026
2025

Fundamental Metrics

Financial Performance
Metric
QLEP
TTRX
Price
$10.08
$9.30
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $25.00
AVG Volume (30 Days)
45.6K
★ 81.3K
Earning Date
N/A
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$900.00
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.93
$2.57
52 Week High
$10.10
$16.45

Technical Indicators

Market Signals
Indicator
QLEP
TTRX
Relative Strength Index (RSI) 56.18 36.09
Support Level N/A $4.98
Resistance Level $10.10 $11.17
Average True Range (ATR) 0.01 0.85
MACD -0.00 -0.13
Stochastic Oscillator 60.00 24.78

Price Performance

Historical Comparison
QLEP
TTRX

About QLEP Quantum Leap Acquisition Corp Class A Ordinary Shares

Quantum Leap Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: